The next generation biopharmaceuticals
Scientific Advisory Board
Prof. Hans Wigzell, M.D., Ph.D.
Professor Emeritus of Microbiology and Tumor Biology, Karolinska Institutet
Prof. Mathias Uhlén, Ph.D.
Professor of Microbiology, Royal Institute of Technology
Affibodys latest Press releases
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Interim Report Q2 (August 23, 2018)